Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
In the Greater Mekong Subregion (GMS) adults are at highest risk for malaria. The most
relevant disease vectors bite during daytime and outdoors which makes forest work a high-risk
activity for malaria. The absence of effective vector control strategies and limited periods
of exposure during forest visits suggest that chemoprophylaxis could be an appropriate
strategy to protect forest workers against malaria.
The investigators propose the use of Artemether-lumefantrine (AL), a drug whose efficacy
remains high in the GMS, unlike, for example DHA/piperaquine [20]. The proposed study will
help to assess the efficacy and feasibility of prophylaxis to prevent malaria in forest
workers, help to identify the optimal regimen, and predict its efficacy in reducing overall
transmission. The proposed study is a critical step for future use of chemoprophylaxis to
protect forest workers in the GMS against malaria.
Phase:
N/A
Details
Lead Sponsor:
University of Oxford
Collaborator:
Global Fund
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Lumefantrine